Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Treatment for Hepatitis C Virus Infection in Adults [Internet].

Chou R, Hartung D, Rahman B, Wasson N, Cottrell E, Fu R.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

2.

Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.

Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R.

Ann Intern Med. 2013 Jan 15;158(2):114-23. Review.

PMID:
23437439
3.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

4.

Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.

Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ.

QJM. 2013 Feb;106(2):153-63. doi: 10.1093/qjmed/hcs214.

5.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032.

PMID:
23602817
6.

Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.

Chou R, Carson S, Chan BK.

J Viral Hepat. 2008 Aug;15(8):551-70. doi: 10.1111/j.1365-2893.2008.00984.x. Erratum in: J Viral Hepat. 2009 May;16(5):376.

PMID:
18482285
7.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014.

PMID:
23707354
8.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Review.

PMID:
22951253
9.

Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.

Ioannou GN, Beste LA, Green PK.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1371-80. doi: 10.1016/j.cgh.2013.12.011.

PMID:
24361415
10.

[Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis].

Yuan XL, Li MY, Zhang DZ.

Zhonghua Gan Zang Bing Za Zhi. 2012 May;20(5):357-62. doi: 10.3760/cma.j.issn.1007-3418.2012.05.011. Chinese.

PMID:
22971281
11.

Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin-A Multicenter Study.

Acharya SK, Sreenivas V, Gupta SD, Kumar S, Chawla YK, Tandon A, Habeeb A, Kar P, Chowdhury A, Choudhuri G, Sarin SK, Amarapurkar D, Arankalle V, Gupte MD, Gupta S, Mukherjee D, Seth D, Goyal R, Tandon BN.

J Clin Exp Hepatol. 2012 Mar;2(1):10-8. doi: 10.1016/S0973-6883(12)60079-6.

12.
13.

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.

Garnock-Jones KP.

Drugs. 2012 Dec 24;72(18):2431-56. doi: 10.2165/11209560-000000000-00000. Review.

PMID:
23231027
14.

Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.

Beste LA, Green PK, Ioannou GN.

Eur J Gastroenterol Hepatol. 2015 Feb;27(2):123-9. doi: 10.1097/MEG.0000000000000241.

PMID:
25503739
15.

Pegylated interferons for the treatment of chronic hepatitis C infection.

Luxon BA, Grace M, Brassard D, Bordens R.

Clin Ther. 2002 Sep;24(9):1363-83. Review.

PMID:
12380630
16.

Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial.

Ferenci P, Caruntu FA, Lengyel G, Messinger D, Bakalos G, Flisiak R.

Infect Dis Ther. 2016 Jun;5(2):113-24. doi: 10.1007/s40121-016-0110-5.

17.

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.

Livingston SE, Townshend-Bulson LJ, Bruden DJ, Homan CE, Gove JE, Plotnik JN, Simons BC, Spradling PR, McMahon BJ.

Int J Circumpolar Health. 2016 Mar 29;75:30696. doi: 10.3402/ijch.v75.30696.

18.

Drug Class Review: Pegylated Interferons for Chronic Hepatitis C Infection: Final Report [Internet].

Chou R, Carson S, Chan BKS, Care B.

Portland (OR): Oregon Health & Science University; 2007 May.

19.

Direct-Acting Antiviral Agents for Chronic Hepatitis C Genotype 1 [Internet].

Murphy G, Farah B, Wong W, Krahn M, Wells G, Chen L, Kelly S, Kaunelis D, Blouin J, Lee K, Carrie A.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Oct.

Items per page

Supplemental Content

Support Center